21998 Federal Register / Vol. 77, No. 71 / Thursday, April 12, 2012 / Notices 

Square, 145 N Street NE., Room 2E–508, 

Washington, DC 20530. 

Jerri Murray, 

Department Clearance Officer, PRA, U.S. 

Department of Justice. 

[FR Doc. 2012–8398 Filed 4–11–12; 8:45 am] 

BILLING CODE 4410–12–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances: 

Notice of Application 

Pursuant to 21 U.S.C. 958(i), the 

Attorney General shall, prior to issuing 

a registration under this Section to a 

bulk manufacturer of a controlled 

substance in schedule I or II, and prior 

to issuing a regulation under 21 U.S.C. 

952(a)(2) authorizing the importation of 

such a substance, provide 

manufacturers holding registrations for 

the bulk manufacture of the substance 

an opportunity for a hearing. 

Therefore, in accordance with 21 CFR 

1301.34(a), this is notice that on 

December 7, 2011, Meda 

Pharmaceuticals Inc., 705 Eldorado 

Street, Decatur, Illinois 62523, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as an importer of Nabilone 

(7379), a basic class of controlled 

substance listed in schedule II. 

The company plans to import the 

listed controlled substance for 

distribution to its customers. 

Any bulk manufacturer who is 

presently, or is applying to be, 

registered with DEA to manufacture 

such basic class of controlled substance 

may file comments or objections to the 

issuance of the proposed registration, 

and may, at the same time, file a written 

request for a hearing on such 

application pursuant to 21 CFR 1301.43, 

and in such form as prescribed by 21 

CFR 1316.47. 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than May 14, 2012. 

This procedure is to be conducted 

simultaneously with, and independent 

of, the procedures described in 21 CFR 

1301.34(b), (c), (d), (e), and (f). As noted 

in a previous notice published in the 

Federal Register on September 23, 1975, 

40 FR 43745–46, all applicants for 

registration to import a basic class of 

any controlled substance listed in 

schedule I or II are, and will continue 

to be, required to demonstrate to the 

Deputy Assistant Administrator, Office 

of Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a); 21 U.S.C. 823(a); and 21 

CFR 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

Dated: April 2, 2012. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2012–8761 Filed 4–11–12; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances, 

Notice of Application, Lipomed, Inc. 

Pursuant to 21 U.S.C. 958(i), the 

Attorney General shall, prior to issuing 

a registration under this Section to a 

bulk manufacturer of a controlled 

substance in schedule I or II, and prior 

to issuing a regulation under 21 U.S.C. 

952(a)(2) authorizing the importation of 

such a substance, provide 

manufacturers holding registrations for 

the bulk manufacture of the substance 

an opportunity for a hearing. 

Therefore, in accordance with 21 CFR 

1301.34(a), this is notice that on January 

30, 2012, Lipomed, Inc., One Broadway, 

Cambridge, Massachusetts 02142, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as an importer of the 

following basic classes of controlled 

substances: 

Drug Schedule 

Cathinone (1235) .......................... I 

Methcathinone (1237) .................. I 

4-methyl-N-methylcathinone 

(1248).

I 

N–Ethylamphetamine (1475) ........ I 

N,N–Dimethylamphetamine 

(1480).

I 

Fenethylline (1503) ....................... I 

Aminorex (1585) ........................... I 

4–Methylaminorex (cis isomer) 

(1590).

I 

Gamma Hydroxybutyric Acid 

(2010).

I 

Methaqualone (2565) ................... I 

Mecloqualone (2572) .................... I 

1–Pentyl-3-(1-naphthoyl)indole 

(7118).

I 

1–Butyl-3-(1-naphthoyl)-indole 

(7173).

I 

1-[2-(4–Morpholinyl)ethyl]-3–1(1- 

naphthoyl) indole (7200).

I 

Alpha-ethyltryptamine (7249) ....... I 

Ibogaine (7260) ............................ I 

5-(1,1–Dimethylheptyl)-2-[(1R,3S)- 

3- 

Drug Schedule 

hydroxycyclohexyl]-phenol (7297) I 

5-(1,1–Dimethyloctyl)-2-[(1R,3S)- 

3- 

hydroxycyclohexyl]-phenol (7298) I 

Lysergic acid diethylamide (7315) I 

2,5–Dimethoxy-4-(n)- 

propylthiophenethylamine 

(7348).

I 

Marihuana (7360) ......................... I 

Tetrahydrocannabinols (7370) ..... I 

Parahexyl (7374) .......................... I 

Nabilone (7379) ............................ I 

Mescaline (7381) .......................... I 

3,4,5–Trimethoxyamphetamine 

(7390).

I 

4–Bromo-2,5- 

dimethoxyamphetamine (7391).

I 

4–Bromo-2,5- 

dimethoxyphenethylamine 

(7392).

I 

4–Methyl-2,5- 

dimethoxyamphetamine (7395).

I 

2,5–Dimethoxyamphetamine 

(7396).

I 

2,5–Dimethoxy-4- 

ethylamphetamine (7399).

I 

3,4–Methylenedioxyamphetamine 

(7400).

I 

5–Methoxy-3,4- 

methylenedioxyamphetamine 

(7401).

I 

N–Hydroxy-3,4- 

methylenedioxyamphetamine 

(7402).

I 

3,4–Methylenedioxy-Nethylamphetamine (7404).I 

3,4– 

Methylenedioxymethamphetamine (7405).

I 

4–Methoxyamphetamine (7411) ... I 

5–Methoxy-N–Ndimethyltryptamine (7431).I 

Alpha-methyltryptamine (7432) .... I 

Dimethyltryptamine (7435) ........... I 

Psilocybin (7437) .......................... I 

Psilocyn (7438) ............................. I 

5–Methoxy-N,Ndiisopropyltryptamine (7439).I 

N–Ethyl-1-phenylcyclohexylamine 

(7455).

I 

1-(1–Phenylcyclohexyl)pyrrolidine 

(7458).

I 

1-[1-(2– 

Thienyl)cyclohexyl]piperidine 

(7470).

I 

1-[1-(2– 

Thienyl)cyclohexyl]pyrrolidine 

(7473).

I 

N–Ethyl-3-piperidyl benzilate 

(7482).

I 

N–Methyl-3-piperidyl benzilate 

(7484).

I 

N–Benzylpiperazine (7493) .......... I 

3,4-methylenedioxypyrovalerone 

(7535).

I 

3,4-methylenedioxy-Nmethylcathinone (7540).I 

Alphaprodine (9010) ..................... I 

Acetyldihydrocodeine (9051) ........ I 

Benzylmorphine (9052) ................ I 

Codeine-N-oxide (9053) ............... I 

Cyprenorphine (9054) .................. I 

Desomorphine (9055) ................... I 

Etorphine (except HCl) (9056) ..... I 

mstockstill on DSK4VPTVN1PROD with NOTICES